Wednesday, July 16, 2025 7/16/2025

The VesiVax? System: Vaccine Development Made Easy

Award Number: R44AI094770
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2012
PERIOD OF PERFORMANCE END DATE: 07/31/2018

Group Awards By:

View Award Description

The VesiVax? System: Vaccine Development Made Easy - ¿ DESCRIPTION (provided by applicant): We have demonstrated in our SBIR Phase I activities that the VesiVax(r) CALV vaccine and adjuvant platform technology can be successfully used to generate formulations containing Toll-like Receptor (TLR) 3 and 7/8 agonists that elicit strong protective immunostimulatory responses in a murine pulmonary influenza challenge model. With the aid of many collaborators and support from the NIAID, we have demonstrated the ability of the VesiVax(r) system to stimulate protective immune responses in a variety of animal models and a range of antigens, using our standard TLR4 agaonist (Monophosphoryl Lipid A). Currently, there is an unmet need for novel, potent immunostimulatory adjuvant molecule (IAM) formulations, and the VesiVax(r) technology platform is designed as a highly flexible vaccine and adjuvant development system. In this revised SBIR Phase II proposal, we intend to expand our VesiVax(r) product portfolio by formulating several other IAMs and focus on further developing the VesiVax(r) formulations for commercial applications. The Specific Aims proposed in this revised SBIR Phase II application include preparation of new VesiVax(r) IAM formulations and engineering scaffold proteins for less immunogenic antigens. We will be testing these formulations, in association with various types of antigens (such as protein, haptens and VLPs), in the murine genital herpes simplex virus 2 challenge model, the murine nicotine addiction model, the murine Chagas disease model, the murine pancreatic cancer model, and the guinea pig genital herpes model.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	MOLECULAR EXPRESS INC	2630 HOMESTEAD PLACE	RANCHO DOMINGUEZ	CA	90220	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	4	1/14/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $736,747 )
2017	2017	MOLECULAR EXPRESS INC	2630 HOMESTEAD PLACE	RANCHO DOMINGUEZ	CA	90220	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	4	7/14/2017	NON-COMPETING CONTINUATION	$736,747
														Subtotal = $736,747

Issue Date FY: 2016 ( Subtotal = $762,253 )
2016	2016	MOLECULAR EXPRESS, INC	1381 WARNER AVE, SUITE C	TUSTIN	CA	90061		USA	Allergy and Infectious Diseases Research	000	3	7/20/2016	COMPETING CONTINUATION	$762,253
														Subtotal = $762,253

Grand Total All Awards = $1,499,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The VesiVax? System: Vaccine Development Made Easy

Award Number: R44AI094770

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2012

PERIOD OF PERFORMANCE END DATE: 07/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer